Quality, comprehensiveness and excellence


Increase in the OECI Accreditation and Designation fee

May 08, 2023 
On 31 January 2023, the OECI Board agreed on an increase of the A&D Accreditation and Designation Fee from € 45,000 to € 55,000.

The fee increase will take effect on 1 April 2023 and is applicable to all centres whose application into the A&D Programme (or re-application through the designation form) is received after 1 April 2023. The Accreditation fee structure will remain a payment in two stages of € 25,000 on application and € 30,000 before the peer review respectively.

The latest OECI standards (Manual 3.2) are now IEEA certified

August 16, 2022 

The certificate was awarded by the ISQua EEA’s International Accreditation Programme, after an independent third-party assessment to validate our standards. As part of the accreditation process OECI has done a rigorous self assessment to check whether our standards complied with the ISQua EEA principles for the Development of Health and Social Care Standards. This was followed by a desk-top survey by the IEEA auditors in May 2022. 

The OECI A&D Standards were developed for cancer centres, with specific standards for cancer care and research.


Requirements for Governance Structures of Cancer Centres which will comply with OECI Standards

July 14, 2022 
Cancer centres are designed to bring together leading clinical expertise across all major cancer types with translational cancer research and education, thus accelerating adoption of novel therapies and enrolment in clinical trials. Most fundamental is the centre’s multidisciplinary character, and its governance as an identifiable entity, often within a larger structure. Standalone cancer centres – founded to treat cancer patients and perform cancer-focused research - generally have a more simple corporate structure.

Revised European Quality Standards for Cancer Networks will be piloted at OncoZON

April 29, 2022 

The OECI A&D Board has approved the revised version (5.3) of the European Quality Standards for Cancer Networks. This revision is based on the experiences of the 1st pilot of the Network standards at the Association Toulousaine d'Oncologie Publique (ATOP) in Toulouse in April 2021. 

The OncoZON (Oncology Network SouthEast Netherlands) Network, consisting of the Maastricht University Medical Centre (MUMC+), 8 other regional hospitals and a radiotherapy institute in Maastricht, has agreed to participate in the 2nd pilot for the OECI European Network Standards certification.


New standards in Manual 3.2 per March 2022

February 24, 2022 
The OECI standards focus on what is critical to cancer care and research. During the IsquaEEA re-accreditation process for our standards, we have reviewed the IEEA standards and found it necessary to add some standards, related to Infection control and Training and support for volunteers, which are essential for cancer care and were missing in Manual 3.1. All centres applying for the A&D Programme for March 2022 will be accredited according to Manual 3.2.

Please find below an overview of the new standards:
Standard 11: Quality Assurance

New chair A&D Board

January 12, 2022 

As of 1 January 2022 Simon Oberst has stepped down as Chair of the A&D Board and will be succeeded by dr. Jean-Benoît Burrion, Deputy Medical Director of Institut Jules Bordet in Brussels.

Simon has been appointed Director of Quality Improvement at OECI from 1 February 2022 and will be responsible for all aspects of Quality Improvement in Cancer Centres, including the A&D Programme and European projects. He will continue to serve on the A&D Board as a non-voting member. OECI wishes both Jean-Benoit and Simon every success in their new roles. 


Call for new auditors OECI A&D Programme

July 21, 2021 

Performing a peer review visit as an OECI auditor is a learning experience in your own professional life, in the fight against cancer in your own Centre, as well as a crucial part of ensuring quality improvement in an applicant Cancer Centre.

During a peer review visit you will have the opportunity to examine all aspects of the Cancer Centre, both the organisation at the management level and at the clinical and laboratory level for all disciplines, e.g. for nurses, physicians, researchers, pathologists, management etc.


100 CORE standards article

May 14, 2021 
In August 2020, the Accreditation and Designation Board of OECI published the results of two years revision work on the Quality Standards for our cancer centres in Europe. Part of this exercise was to select by consensus the Core Standards for quality care and research infrastructure which would be regarded as essential to apply across Europe, and which OECI will use as core requirements in every (re-)accreditation of a cancer centre, and require full evidence of compliance. .

European Cancer Network Standards evaluated in pilot visit

May 14, 2021 

Building upon our highly successful quality accreditation programme for Cancer Centres and Comprehensive Cancer Centres (now involving nearly 60 large centres, with our standards being certified by ISQua) the A&D programme has now developed (with the aid of multiple professional and patient organisations) a set of quality standards for cancer networks, which evaluate the effectiveness of each cancer network structure.  These European Cancer Network Standards are in draft form and are being evaluated in pilot visits.


Revisions Appendix III Manual 3.0 (Quantitative questionnaire)

April 15, 2021 Pharmacy with unit dedicated to Oncology (instead of Oncology Pharmacy) Definition accrual into prospective interventional trials:
Participants in cohort-based observational biomarker-driven studies are NOT included in the number forming the percentage for Designation. We do ask for the data of cohort-based observational studies (see question ), provided that they concern studies with a formal PI role from the centre, and approved by scientific and ethical review committees.

1 2 3 4 5